Ascentage Pharma Group International AAPG
NASDAQ AAPG
$15.90 -0.59 (-3.63%)
As of: Oct 1, 2026 · 2:20 PM EDT

Ascentage Pharma Group International (AAPG) Accounts Payables (2023 - 2026)

Updated

Ascentage Pharma Group International (AAPG) recorded Accounts Payables of $15.76 million in Q2 2026, down 4.9% from $16.57 million a year earlier.

Analysis

Ascentage Pharma Group International (AAPG) Accounts Payables (2023 - 2026) Analysis & Trends

At the end of FY2025, Ascentage Pharma Group International reported Accounts Payables of $15.26 million, up 21.2% from FY2024.

  • Across earlier years, Accounts Payables came in at $12.6 million in FY2024 (+22.9%) and $10.25 million in FY2023.
  • Quarterly Accounts Payables has ranged from $10.06 million in Q4 2023 to $16.57 million in Q2 2025 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Accounts Payables (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 9.22 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 33.30 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 3.83 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 4.26 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -22.89 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 2.87 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 674.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 4.58 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 429.50 Mn
10 Ascentage Pharma Group International 1.55 Bn 517.76 Mn - 15.76 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 15.76 Mn
Dec 31, 2025 15.05 Mn
Jun 30, 2025 16.57 Mn
Dec 31, 2024 12.80 Mn
Dec 31, 2023 10.06 Mn
API Access

Ascentage Pharma Group International Accounts Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accounts-payables&ticker=AAPG&period=max&api_key=YOUR_API_KEY